ESTRO 2024 - Abstract Book

S1576

Clinical - Lung

ESTRO 2024

The 6 PCs derived from changes at 6 weeks after radiotherapy are described in table 1 . At 6 weeks, a decrease in left ventricle outflow speed (PC1) was independently predicted by LV5 (B=-0.022; P=0.01). This association was most pronounced in patients without induction chemotherapy (B=-0.022; P=0.01)), without COPD (B=-0.024; P<0.01), or without cardiovascular comorbidity (B=-0.027; P<0.01).

An increase in left ventricular mass and size (PC5) at 6 weeks was independently associated with MHD (B=0.06; P<0.01) regardless of other treatments and comorbidities.

The 6 PCs derived from changes at 1 year after radiotherapy are described in table 2 . Although change in PC1 at one year after treatment was not independently associated with MLD in the total population (B=0.03; P=0.64), for patients with cardiovascular comorbidity an increase in PC1 was associated with MLD (B=0.26; P<0.01).

One year after radiotherapy, an increase in left ventricular mass and size (PC5) was independently predicted by LV5 (B=0.02; P=0.02), MHD (B=0.07; P=0.047) and MLD (B=0.12; P=0.02), respectively. In patients who did not receive